학술논문

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial
Document Type
Article
Author
Marson, AnthonyBurnside, GirvanAppleton, RichardSmith, DaveLeach, John PaulSills, GraemeTudur-Smith, CatrinPlumpton, CatrinHughes, Dyfrig AWilliamson, PaulaBaker, Gus ABalabanova, SilviyaTaylor, ClaireBrown, RichardHindley, DanHowell, StephenMaguire, MelissaMohanraj, RajivSmith, Philip ELanyon, KarenManford, MarkChitre, ManaliParker, AlasdairSwiderska, NinaAppleton, RichardPauling, JamesHughes, AdrianGupta, RajatHanif, SadiaAwadh, MostafaRagunathan, SharminiCable, NicolaCooper, PaulHindley, DanielRakshi, KarlMolloy, SophieReuber, MarkusAyonrinde, KunleWilson, MartinSaladi, SatyanarayanaGibb, JohnFunston, Lesley-AnnCassidy, DamhaitBoyd, JonathanRatnayaka, MalFaza, HaniSadler, MartinAl-Moasseb, HassanGaltrey, ClareWren, DamienOlabi, AnasFuller, GeraintKhan, MuhammedKallappa, ChetanaChinthapalli, RaviAji, BabaDavies, RhysFoster, KathrynHitiris, NikolasMaguire, MelissaHussain, NahinDowson, SimonEllison, JulieSharrack, BasilGandhi, VandnaPowell, RobTittensor, PhilSummers, BeatriceShashikiran, SastryDison, Penelope JSamarasekera, ShanikaMcCorry, DougWhite, KathleenNithi, KannanRichardson, MartinBrown, RichardPage, RupertDeekollu, DavidSlaght, SeanWarriner, StephenAhmed, MansoorChaudhuri, AbhijitChow, GabrielArtal, JavierKucinskiene, DanuteSreenivasa, HarishVelmurugan, SingaraZipitis, Christos SMcLean, BrendanLal, VaithianatharGregoriou, AngelousMaddison, PaulPickersgill, TrevorAnderson, JosephLawthom, CharlotteHowell, StephenWhitlingum, GabrielRakowicz, WojtekKinton, LucyMcLellan, AlisaVora, NitishZuberi, SameerKelso, AndrewHughes, ImeldaMartland, JohnEmsley, Hedleyde Goede, ChristianSingh, RPMoor, Carl-ChristianAram, JuliaMohanraj, RajivSakthivel, KumarNelapatla, SureshRittey, ChrisPinto, AshwinLeach, John PaulCock, HannahRichardson, AnnaHouston, ErikaCooper, ChristopherLawson, GeoffMassarano, AlbertBurness, ChristineMarson, AnthonySmith, DaveWieshmann, UdoDey, IndranilSivakumar, PuthuvalYeung, Lap-KongSmith, PhilipBentur, HemalataHeafield, TomMathew, AnnaSmith, DavidJauhari, Praveen
Source
The Lancet; April 2021, Vol. 397 Issue: 10282 p1363-1374, 12p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, but there is uncertainty as to whether they should be recommended as first-line treatments because of insufficient evidence of clinical effectiveness and cost-effectiveness. We aimed to assess the long-term clinical effectiveness and cost-effectiveness of levetiracetam and zonisamide compared with lamotrigine in people with newly diagnosed focal epilepsy.